620
Participants
Start Date
June 30, 2013
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Neoadjuvant Chemoradiotherapy
Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy \[Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle (non-concurrent); Oxaliplatin 100 mg/m² IV on Day 1 + Capecitabine 825 mg/m² orally BID on Days 1-14 of a 21-day cycle (concurrent chemoradiotherapy)\]
Neoadjuvant Chemotherapy
3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
R0 D2 Gastrectomy
Adjuvant Chemotherapy
3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
Sun Yat-sen University Cancer Center, Guangzhou
The First Affiliated Hospital of Anhui Medical University
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Guangdong Provincial Hospital of Traditional Chinese Medicine
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Zhejiang Cancer Hospital
OTHER
First Hospital of China Medical University
OTHER
The Affiliated Tumor Hospital of Guangxi Medical University
UNKNOWN
Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry
UNKNOWN
The Affiliated Hospital of Qingdao University
OTHER
Guangdong Provincial People's Hospital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
National Clinical Research Center for Cancer/Cancer Hospital
UNKNOWN
Sun Yat-sen University
OTHER